Principle Investigator: Samir Khleif, MD “D4193C00001; A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)” Sponsor: AstraZeneca...
Clinical trials testing vaccine-mediated therapy against malignant melanoma have generated disappointing responses. The laboratory of Esteban Celis, MD, PhD, at the GRU Cancer Center proposes that this is due to an insufficient number of antigen...
Researchers and healthcare workers from across the region gathered at GRU on September 18, 2015 for a CME-certified, full-day program, “Tumor Immunology 101: A Navigation Guide for the Growing Field of Cancer Immunotherapy,” organized by GRU Cancer...
Samir N. Khleif, MD Director, GRU Cancer Center “When you are finished changing, you are finished.” — Benjamin Franklin It doesn’t take much, just a few steps out our front door, to be reminded that nothing in this life is...
Researchers led by Kebin Liu, PhD, in collaboration with colleagues including other members of the GRU Cancer Center, Drs. McGaha, Zhou, and Mellor, have demonstrated for the first time a novel mechanism through which the adaptive immune system...
Last year, Theodore S. Johnson, MD, PhD, was awarded Georgia Regents University/Medical College of Georgia’s first grant from Alex’s Lemonade Stand Foundation (ALSF), an organization devoted to promoting research on childhood cancers. This three...
As published in The Journal of Immunology, Santhakumar Manicassamy, PhD, and colleagues including Cancer Center members Drs. Mellor and Munn, have discovered how the immune system’s dendritic cells suppress autoimmune inflammation. Furthermore, they...
CitationNagato T, Lee YR, Harabuchi Y, Celis E. Combinatorial Immunotherapy of Polyinosinic-Polycytidylic Acid and Blockade of Programmed Death-1 Induces Effective CD8 T Cell Responses against Established Tumors.Clin Cancer Res. 2014 Jan 3. [Epub...
Vadivel Ganapathy, PhD., Biochemistry and Molecular Biology, received a 3-year, $562,500 grant from the Department of Defense for Homocysteine Is an Oncometabolite in Breast Cancer, Which Promotes Tumor Progression and Metastasis. This project is...
Researchers at the GRU Cancer Center have discovered a way to give the immune system a boost in its ability to recognize tumor cells as “enemy” agents. Cancer vaccines have been a growing field in cancer therapeutics, where the body’s immune system...